• Ken Kuljit S Parhar, Andrea Soo, Gwen Knight, Kirsten Fiest, Daniel J Niven, Gordon Rubenfeld, Damon Scales, Henry T Stelfox, Danny J Zuege, and Sean Bagshaw.
• Department of Critical Care Medicine, University of Calgary & Alberta Health Services, Calgary, Alberta, Canada.
• Crit Care Resusc. 2023 Dec 1; 25 (4): 207215207-215.

ObjectiveTo describe a study protocol and statistical analysis plan (SAP) for the identification and treatment of hypoxemic respiratory failure (HRF) and acute respiratory distress syndrome (ARDS) with protection, paralysis, and proning (TheraPPP) study prior to completion of recruitment, electronic data retrieval, and analysis of any data.DesignTheraPPP is a stepped-wedge cluster randomised study evaluating a care pathway for HRF and ARDS patients. This is a type-1 hybrid effectiveness-implementation study design evaluating both intervention effectiveness and implementation; however primarily powered for the effectiveness outcome.SettingSeventeen adult intensive care units (ICUs) across Alberta, Canada.ParticipantsWe estimate a sample size of 18816 mechanically ventilated patients, with 11424 patients preimplementation and 7392 patients postimplementation. We estimate 2688 sustained ARDS patients within our study cohort.InterventionAn evidence-based, stakeholder-informed, multidisciplinary care pathway called Venting Wisely that standardises diagnosis and treatment of HRF and ARDS patients.Main Outcome MeasuresThe primary outcome is 28-day ventilator-free days (VFDs). The primary analysis will compare the mean 28-day VFDs preimplementation and postimplementation using a mixed-effects linear regression model. Prespecified subgroups include sex, age, HRF, ARDS, COVID-19, cardiac surgery, body mass index, height, illness acuity, and ICU volume.ResultsThis protocol and SAP are reported using the Standard Protocol Items: Recommendations for Interventional Trials guidance and the Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. The study received ethics approval and was registered (ClinicalTrials.gov-NCT04744298) prior to patient enrolment.ConclusionsTheraPPP will evaluate the effectiveness and implementation of an HRF and ARDS care pathway.© 2023 The Authors.

5 keywords...

hide…